Cancer Stem Cell News Volume 10.19 | May 19 2021


    2021-05-19 | CSCN 10.19

    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 10.19 – 19 May, 2021

    Stem-Like Cells Drive NF1-Associated MPNST Functional Heterogeneity and Tumor Progression

    Investigators discovered and characterized a rare malignant peripheral nerve sheath tumor (MPNST) cell population with stem-cell-like properties, including quiescence, that was essential for tumor initiation and relapse.
    [Cell Stem Cell]

    AbstractGraphical Abstract

    Attend the Cancer Stem Cells: Advances in Biology and Clinical Translation Virtual Meeting
    PUBLICATIONSRanked by the impact factor of the journal

    RANK Links Senescence to Stemness in the Mammary Epithelia, Delaying Tumor Onset but Increasing Tumor Aggressiveness

    The authors uncovered a dual role for Rank in the mammary epithelia: Rank induced senescence and stemness, delaying tumor initiation but increasing tumor aggressiveness.
    [Developmental Cell]

    Full ArticleGraphical Abstract

    Clinically Relevant Aberrant Filip1l DNA Methylation Detected in a Murine Model of Cutaneous Squamous Cell Carcinoma

    Scientists found increased average methylation in mouse cutaneous squamous cell carcinomas (cSCC) as well as in stem-cell-like, but not keratinocyte-like, human cSCC.

    Full Article

    Bone Marrow Mesenchymal Stem Cells Promote Prostate Cancer Cell Stemness via Cell–Cell Contact to Activate the Jagged1/Notch1 Pathway

    The authors investigated the effect of direct contact of prostate cancer (PCa) cells with mesenchymal stem cells on the stemness of PCa and its mechanisms.
    [Cell and Bioscience]

    Full Article

    Aspartame Induces Cancer Stem Cell Enrichment through p21, NICD and GLI1 in Human PANC-1 Pancreas Adenocarcinoma Cells

    Researchers indicated that a high level of glucose exposure does not affect the invasion and migration of PANC-1 cells, while aspartame increases both of these aggressiveness criteria.
    [Food and Chemical Toxicology]


    ID4 Predicts Poor Prognosis and Promotes BDNF-Mediated Oncogenesis of Colorectal Cancer

    The expression of Inhibitor of DNA binding and cell differentiation 4 (ID4), but not other ID family proteins, was enriched in LGR5-high colon cancer stem cells.


    CD133 mRNA Transfected Dendritic Cells Induces a Coordinated Cytotoxic and Helper T Cell Responses against Breast Cancer Stem Cells

    Investigators hypothesized that by creating an MHC independent vaccination, they would give rise to a sustained immune response against CD133 in triple-negative breast carcinomas.
    [Molecular Therapy-Oncolytics]

    AbstractFull ArticleGraphical Abstract

    Clinical Significance of Circulating Tumor Cell Related Markers in Patients with Epithelial Ovarian Cancer Before and after Adjuvant Chemotherapy

    Using quantitative real-time PCR, the authors evaluated the expression of EPCAM, MUC1, CEA, HE4, and CA125 mRNAs, as putative markers of circulating tumor cells, in the blood of 51 epithelial ovarian cancer patients before and/or after adjuvant chemotherapy.
    [Scientific Reports]

    Full Article

    Cancer Stem Cell Marker DCLK1 Reprograms Small Extracellular Vesicles toward Migratory Phenotype in Gastric Cancer Cells

    Researchers reported that doublecortin‐like kinase 1 (DCLK1) influences small extracellular vesicle biogenesis in a kinase‐dependent manner.


    Find the Right Antibodies for Your Stem Cell Research. Learn More

    Hematopoietic versus Leukemic Stem Cell Quiescence: Challenges and Therapeutic Opportunities

    Scientists summarize the current knowledge on the biochemical characteristics of quiescent hematopoietic stem cells (HSCs) and leukemic stem cells (LSCs), the intracellular signaling pathways and the niche-driven mechanisms that control quiescence and the key differences between HSC- and LSC-quiescence.
    [Blood Reviews]

    Full Article

    Progress and Application of Circulating Tumor Cells in Non-Small Cell Lung Cancer

    Investigators discuss the technologies for detection and enrichment of circulating tumor cells, as well as clinical applications involving circulating tumor cells.
    [Molecular Therapy-Oncolytics]

    AbstractFull ArticleGraphical Abstract


    Context Therapeutics® and Jefferson Health Announce First Patient Dosed in Phase II Trial of ONA-XR in Advanced Endometrial Cancer

    Context Therapeutics, Inc. and the Sidney Kimmel Cancer Center – Jefferson Health, announced the first patient has been dosed in the Phase II ONWARD 221 trial in patients with metastatic endometrial cancer.
    [Context Therapeutics, Inc.]

    Press Release

    Coeptis Pharmaceuticals Enters Into Exclusive Option Agreements with VyGen-Bio to Co-Develop Technologies Designed to Improve the Treatment of CD38-Related Cancers

    Coeptis Pharmaceuticals, Inc., has announced entry into two separate exclusive option agreements with VyGen-Bio, Inc., a majority-owned subsidiary of Vycellix, Inc., involving technologies being studied to potentially improve the treatment of CD38-related cancers.
    [Coeptis Pharmaceuticals, Inc. (Cision US, Inc.)]

    Press Release


    ISSCR 2021 Annual Meeting

    June 21 – 26, 2021

    > See All Events


    Research Associate – Cancer Stem Cell Biology

    City of Hope – Duarte, California, United States

    Postdoctoral Scientist – Non-Classical Mechanisms of Therapy Resistance

    Cedars-Sinai – Los Angeles, California, United States

    Postdotoral Research Fellow – Cancer Stem Cells of Liver Cancer and Tumor Immunology

    National Institutes of Health – Bethesda, Maryland, United States

    Postdotoral Research Fellow – Cancer Stem Cells

    Virginia Commonwealth University – Richmond, Virginia, United States

    Research Fellow – Intestinal Stem Cells & Gastrointestinal Diseases

    Case Western Reserve University – Cleveland, Ohio, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Cancer Stem Cell News Twitter